A Novel Activating Mutation in the RET Tyrosine Kinase Domain Mediates Neoplastic Transformation
Open Access
- 1 July 2006
- journal article
- case report
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 20 (7) , 1633-1643
Abstract
We report the finding of a novel missense mutation at codon 833 in the tyrosine kinase of the RET proto-oncogene in a patient with a carcinoma of the thyroid. In vitro experiments demonstrate that the R833C mutation induces transformed foci only when present in the long 3′ splice isoform and, in keeping with a model in which the receptor has to dimerize to be completely activated, glial cell line-derived neurotrophic factor stimulation leads the RETR833C receptor to a higher level of activation. Tyrosine kinase assays show that the RETR833C long isoform has weak intrinsic kinase activity and phosphorylation of an exogenous substrate is not elevated even in the presence of glial cell line-derived neurotrophic factor. Furthermore, the R833C mutation is capable of sustaining the transformed phenotype in vivo but does not confer upon the transformed cells the ability to degrade the basement membrane in a manner analogous to metastasis. Our functional characterization of the R833C substitution suggests that, like the V804M and S891A mutations, this tyrosine kinase mutation confers a weak activating potential upon RET. This is the first report demonstrating that the introduction of an intracellular cysteine can activate RET. However, this does not occur via dimerization in a manner analogous to the extracellular cysteine mutants.Keywords
This publication has 37 references indexed in Scilit:
- A Two-Hit Model for Development of Multiple Endocrine Neoplasia Type 2B by RET MutationsBiochemical and Biophysical Research Communications, 2000
- The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor proteinOncogene, 1999
- Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinomaOncogene, 1999
- Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulationOncogene, 1998
- Germline mutation of RET codon 883 in two cases of de novo MEN 2BOncogene, 1997
- Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domainOncogene, 1997
- Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of theRET proto-oncogeneInternational Journal of Cancer, 1996
- RET Mutation Screening in MEN2 Patients and Discovery of a Novel Mutation in a Sporadic Medullary Thyroid CarcinomaThyroid®, 1996
- The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A familiesClinical Endocrinology, 1996
- Low frequency of germline mutations in the RET proto‐oncogene in patients with apparently sporadic medullary thyroid carcinomaClinical Endocrinology, 1995